BioNTech builds huge vaccine factory in SingaporeEuropost
BioNTech unveiled massive investment plans related to establishing regional headquarters and building brand new manufacturing site for its RNA vaccines in Singapore, in the latest move to boost opperations in its production network, Reuters reported. The pharmaceutical company earmarked Singapore output facility would have an estimated annual capacity of several hundred million doses of mRNA-based vaccines depending on the specific type, once it is operational in 2023.
BioNTech noted its expansion plans were supported by the Singapore Economic Development Board and would increase the global supply of mRNA-based vaccines and establish a production facility in south east Asia to respond rapidly to future pandemics.
"Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities," said Ugur Sahin, CEO and Co-founder of BioNTech.
Governments around the world are looking to build up local vaccine production to secure access to supplies after manufacturing setbacks have slowed the rollout of COVID-19 doses in some countries.
The establishment of a southeast Asia regional hub comes after BioNTech, based in Mainz, Germany, set up a US headquarters in Cambridge, Massachusetts in 2020.